US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL.

Autor: Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Othus M; SWOG Statistical Center, Seattle, WA., O'Brien SM; University of California - Irvine, Orange, CA., Forman SJ; City of Hope National Medical Center, Duarte, CA., Ha CS; University of Texas Health Science Center, San Antonio, TX., Wong JYC; City of Hope National Medical Center, Duarte, CA., Tallman MS; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Paietta E; Cancer Center, Montefiore Medical Center, Bronx, NY.; Albert Einstein College of Medicine, New York, NY., Racevskis J; Cancer Center, Montefiore Medical Center, Bronx, NY.; Albert Einstein College of Medicine, New York, NY., Uy GL; Division of Oncology, Washington University School of Medicine, St. Louis, MO., Horowitz M; Medical College of Wisconsin, Milwaukee, WI., Takebe N; Cancer Therapy Evaluation Program, Investigational Drug Branch, Bethesda, MD., Little R; Cancer Therapy Evaluation Program, Investigational Drug Branch, Bethesda, MD., Borate U; University of Alabama at Birmingham, Birmingham, AL., Kebriaei P; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX., Kingsbury L; SWOG Statistical Center, Seattle, WA., Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX., Radich JP; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Erba HP; University of Alabama at Birmingham and UAB Comprehensive Cancer Center, Birmingham, AL., Appelbaum FR; Fred Hutchinson Cancer Research Center, Seattle, WA.

Publikováno v: Blood advances [Blood Adv] 2016 Dec 27; Vol. 1 (3), pp. 250-259.